Thelansis

Blue Cone Monochromatism (BCM) Market Outlook Thelansis’s “Blue Cone Monochromatism (BCM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Blue Cone Monochromatism (BCM) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact o...

Blue Cone Monochromatism (BCM) Market Outlook Thelansis’s “Blue Cone Monochromatism (BCM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Blue Cone Monochromatism (BCM)     treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Blue Cone Monochromatism (BCM) Overview Blue cone monochromatism (BCM) is a rare X-linked congenital cone dysfunction syndrome, caused by mutations in the OPN1LW/OPN1MW gene cluster on the X chromosome. The cluster contains a single OPN1LW and one or more copies of the OPN1MW gene and controls the expression of the red (L, long wavelength) and green (M, middle wavelength) cone photoreceptor opsins. The gen...

Blue cone monochromatism (BCM) is a rare X-linked congenital cone dysfunction syndrome, caused by mutations in the OPN1LW/OPN1MW gene cluster on the X chromosome. The cluster contains a single OPN1LW and one or more copies of the OPN1MW gene and controls the expression of the red (L, long wavelength) and green (M, middle wavelength) cone photoreceptor opsins. The genes expressing the opsin for the third cone subtype, S (short-wavelength) or blue cones (OPN1SW), and the rod pigment are autosomal and not affected in BCM. Consequently, vision in affected males is subserved only by S cone and rod function, as no functional L or M cones are present in the retina while Tritan discrimination, which has been reported to deteriorate with increasing illuminance and scotopic perception are retained. ·        The prevalence of Blue cone monochromatism (BCM) varies between 1 to 1.75 cases per 100,000 population. Colour discrimination is severely impaired from birth and ...

 Blue cone monochromatism (BCM) is a rare X-linked congenital cone dysfunction syndrome, caused by mutations in the OPN1LW/OPN1MW gene cluster on the X chromosome. The cluster contains a single OPN1LW and one or more copies of the OPN1MW gene and controls the expression of the red (L, long wavelength) and green (M, middle wavelength) cone photoreceptor opsins. The genes expressing the opsin for the third cone subtype, S (short-wavelength) or blue cones (OPN1SW), and the rod pigment are autosomal and not affected in BCM. Consequently, vision in affected males is subserved only by S cone and rod function, as no functional L or M cones are present in the retina while Tritan discrimination, which has been reported to deteriorate with increasing illuminance and scotopic perception are retained. ·        The prevalence of Blue cone monochromatism (BCM) varies between 1 to 1.75 cases per 100,000 population. Colour discrimination is severely impaired from bi...

  Blue cone monochromatism (BCM) is a rare X-linked congenital cone dysfunction syndrome, caused by mutations in the OPN1LW/OPN1MW gene cluster on the X chromosome. The cluster contains a single OPN1LW and one or more copies of the OPN1MW gene and controls the expression of the red (L, long wavelength) and green (M, middle wavelength) cone photoreceptor opsins. The genes expressing the opsin for the third cone subtype, S (short-wavelength) or blue cones (OPN1SW), and the rod pigment are autosomal and not affected in BCM. Consequently, vision in affected males is subserved only by S cone and rod function, as no functional L or M cones are present in the retina while Tritan discrimination, which has been reported to deteriorate with increasing illuminance and scotopic perception are retained. The prevalence of Blue cone monochromatism (BCM) varies between 1 to 1.75 cases per 100,000 population. Colour discrimination is severely impaired from birth and BCM patients typically present...